THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085Exclusive License Agreement • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
This Third Amendment to Exclusive License Agreement (“Thir d Amendment”), dated as of June 12, 2006, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc, a Delaware corporation and subsidiary of Medivation (“MPT”) (Medivation and MPT together “Licensee”).
Body text (2);Body text;Heading #4;AMENDMENT NO. 4 TO COLLABORATION AGREEMENTCollaboration Agreement • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
This Amendment No. 4 (this “Amendment”) is entered into this 29th day of October, 2013 (“Amendment Effective Date”), by and among MEDIYATION, INC., a Delaware corporation having its principal place of business at 525 Market Street, 36th Floor, San Francisco, California 94105, United States, its wholly owned subsidiary MEDIVATION PROSTATE THERAPEUTICS, INC., a Delaware corporation having its principal place of business at the same location (such entities, collectively, “Medivation”), ASTELLAS PHARMA INC., a Japanese corporation having its principal place of business at 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“API”) and its indirect wholly owned subsidiary Astellas US LLC, a Delaware limited liability company having its principal place of business at 1 Astellas Way, Northfield, Illinois 60062, United States (“AUS”; collectively with API, “Astellas”) and amends the Collaboration Agreement effective as of October 26, 2009 as previously amended (the “Collaboration Ag
FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085Exclusive License Agreement • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
Body text (2);Body text;FIRST AMENDMENT TO OFFICE LEASEOffice Lease • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO OFFICE LEASE (this “Amendment”) is made and entered into as of December 28, 2011 (the “Effective Date”) by and between KNICKERBOCKER PROPERTIES, INC. XXXIII, a Delaware corporation (the “Landlord”), and MEDIVATION, INC., a Delaware corporation (the “Tenant”).
Body text (2);Body text1;AMENDMENT NO. 5 TO COLLABORATION AGREEMENT This Amendment No. 5 (this “Amendment”) is entered into this 6 day of RECITALSCollaboration Agreement • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
WHEREAS, on March 24, 2014, the MHLW in Japan approved the MDY3100 Product for the indication “Castration Resistant Prostate Cancer” (the “ J-NDA”) with a precaution in the label stating that efficacy and safety of the MDV3100 Product in chemotherapy-na’ive patients with prostate cancer have not been established (the “Precautionary Statement”);
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085Exclusive License Agreement Uc Agreement • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
California, a California corporation (“The Regents”), Medivation, Inc , a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc , a Delaware corporation and subsidiary of Medivation (“MPT”)
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085Exclusive License Agreement • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
This First Amendment to Exclusive License Agreement (this “Amendment”), dated as of November 4, 2005, is made by and among The Regents of the University of
AMENDMENT TO CONSULTING AGREEMENTConsulting Agreement • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
This Amendment (the “Amendment”) hereby amends the Consulting Agreement dated July 14, 2014 between Medivation, Inc. (collectively with its subsidiaries, the “Company”) and Dawn Svoronos (“Consultant”)(the “Agreement”), effective as of October 14, 2014.
Body text (2);Body text1;AMENDMENT NO.3 TO COLLABORATION AGREEMENTCollaboration Agreement • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
This Amendment No. 3 to the Collaboration Agreement (this “Amendment”) is entered into and effective as of April 1, 2013 (the “Amendment Effective Date”) by and among MEDIVATION, INC., a Delaware corporation having its principal place of business at 525 Market Street, 36th Floor, San Francisco, California 94105, United States, its wholly owned subsidiary Medivation Prostate Therapeutics, Inc., a Delaware corporation having its principal place of business at the same location (such entities, collectively, “Medivation”), ASTELLAS PHARMA INC., a Japanese corporation having a principal office at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“API”) and its indirect wholly owned subsidiary Astellas US LLC, a Delaware limited liability company having its principal place of business at 1 Astellas Way, Northbrook, IL 60062 , United States (“AUS”; collectively with API, “Astellas”). Medivation and Astellas are sometimes referred to herein individually as a “Party” and collecti
Four th Amendment To Exclusive License Agreement Between The Regents of the University of California and Medivation, Inc and Medivation Prostate Therapeutics, Inc For UC Agreement Control No. 2006-04-0085Exclusive License Agreement • February 25th, 2015 • Medivation, Inc. • Pharmaceutical preparations
This Fourth Amendment to Exclusive License Agreement (“Fourth Amendment”), dated as of July 17, 2007, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc , a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc,, a Delaware corporation and subsidiary of Medivation (“MPT”) (Medivation and MPT together “Licensee”)
